Statement of Principles concerning cerebral meningioma (Reasonable Hypothesis) (No. 1 of 2018)

The central legal concept is the “reasonable hypothesis”, a standard of proof under the VEA and MRCA that is lower than the balance of probabilities. The SoP operationalises that standard by listing factors that, if present and related to service, are sufficient to raise a reasonable hypothesis. The instrument does not require proof of causation on the balance of probabilities; it only requires that the hypothesis is not contrary to proved or known scientific facts. The SoP binds decision-makers to accept a hypothesis that fits within its factors, but it also excludes any hypothesis not listed. “Relevant service” is defined in the dictionary and includes operational service, peacekeeping service, hazardous service, British nuclear test defence service under the VEA, and warlike or non-warlike service under the MRCA. “Cerebral meningioma” is defined as a primary benign or intermediate grade tumour of the cerebral meninges. It attracts ICD-10-AM codes D32.0 or D32.9 but the definition in subsection 7(2) governs. The SoP does not cover malignant meningioma. “Cumulative equivalent dose” is the total dose of ionising radiation to the brain from external and internal exposure, excluding normal Australian background radiation, calculated per the ARPANSA guide of August 2017. The threshold is at least 0.1 sievert, with a latency of at least five years before clinical onset. “Being overweight or obese” is defined by BMI of 25 or greater, maintained for at least five years within the 20 years before clinical onset. This is a relatively low threshold, capturing many people who are merely overweight, not obese. “Being treated with a drug as specified” is a narrow category: only medroxyprogesterone acetate at ≥15 mg/day, cyproterone acetate at ≥15 mg/day, chlormadinone acetate at ≥50 mg/day, or megestrol acetate at ≥50 mg/day, each for a continuous period of at least one year. This excludes many other hormone therapies and contraceptives. “Hormone replacement therapy” means administration of estrogen preparations often combined with progesterone to offset a hormone deficiency following surgically induced or naturally occurring menopause. Use for at least six months before onset, with a 10-year post-cessation window. “Terminal event” includes pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function. The concept of “clinical worsening” is recognised only for factors in subsections 9(6) to 9(8), which apply to aggravation of a pre-existing condition. The SoP’s dictionary also incorporates other SoPs by reference through section 11, meaning that if a factor in this SoP refers to an injury or disease covered by another SoP (e.g., a drug causing another condition), that other SoP’s factors must also be satisfied. This creates a layered causation framework.

The primary class affected is Australian veterans and members who render “relevant service” as defined: operational, peacekeeping, hazardous, or British nuclear test defence service under the VEA, and warlike or non-warlike service under the MRCA. This includes current and former members of the Australian Defence Force, Peacekeeping Forces, and those involved in British nuclear testing. Their dependents are also affected in claims for death from cerebral meningioma. The instrument also directly affects decision-makers: delegates of the Repatriation Commission, the Military Rehabilitation and Compensation Commission, and the Veterans’ Review Board, who must apply the factors strictly. Legal practitioners and advocates representing claimants must understand the narrow definitions and timeframes to build a case. Medical practitioners who provide expert evidence must frame their opinions around the specified thresholds, such as radiation dose calculation or BMI history. The instrument also affects the Repatriation Medical Authority itself, which must defend its determination if challenged. The SoP may indirectly affect insurers, health providers, and employers of veterans, but only through the compensation system. Because the SoP replaces the 2009 version, any claimant whose case was previously assessed under the old instrument and who is now reapplying must meet the new factors. The instrument applies to claims to which section 120A of the VEA or section 338 of the MRCA apply, essentially all new claims after commencement. For claims that were already lodged but not finally determined before 29 January 2018, the Registrar may apply the new SoP. The economic impact is concentrated on the Commonwealth budget, as accepted claims result in pension or compensation payments. The SoP may increase or decrease the number of successful claims relative to the 2009 instrument, depending on how the factors differ. For example, the new drug list may be narrower, while the obesity factor may be broader. The instrument also affects the administrative cost of processing claims, as fact-finding for factors like cumulative radiation dose requires expert calculations and potentially expensive reconstruction. Private choice is affected because the SoP does not consider factors that a claimant might believe caused their condition but are not listed, such as other types of radiation exposure not captured by the ARPANSA guide, or other medications. This reduces the freedom of claimants to present alternative causal theories. The instrument centralises causation determinations in the RMA, removing individual decision-maker discretion.

The SoP does not impose duties directly on claimants, but to succeed in a claim they must demonstrate that at least one factor in section 9 existed and was related to their relevant service. Claimants have the right to have their claim assessed against the SoP factors. If they satisfy the factors, they are entitled to the benefit of the reasonable hypothesis standard, meaning the claim should succeed unless the decision-maker can prove beyond reasonable doubt that the condition was not service-related. There is a right to apply for reconsideration or review of an adverse decision. The RMA has the duty under subsection 196B(2) to determine SoPs based on sound medical-scientific evidence. This instrument represents the discharge of that duty for cerebral meningioma. The RMA also has the duty to revoke earlier instruments, which it did in section 4. Decision-makers under the VEA and MRCA have a duty to apply this SoP to claims. They cannot disregard the factors or substitute their own views. If a factor refers to another injury or disease covered by another SoP, section 11 imposes a duty on the decision-maker to also apply that other SoP. Claimants have a right to rely on the dictionary definitions, which are binding. For example, “being treated with a drug as specified” must be assessed strictly: a claimant taking cyproterone acetate at 10 mg/day for two years does not meet the factor, even if the drug is otherwise identical. This creates a right of certainty but also a right of exclusion. The instrument does not grant any right to challenge the SoP itself except through judicial review under the Administrative Decisions (Judicial Review) Act 1977 or the Constitution. There is a right to obtain reasons for a decision. Importantly, the SoP does not create any duty to warn or inform veterans about risk factors; it is purely a claim assessment tool. The instrument also imposes a duty on the Commonwealth to pay compensation when a claim is accepted under the SoP. The relationship to service requirement in section 10 means the factor must have been caused or contributed to by service. This imposes an evidentiary duty on the claimant to link the factor to service. For example, if the factor is obesity, the claimant must show the obesity was related to service, such as through a service injury or condition that led to weight gain. The SoP does not alter the substantive standard of proof; it merely specifies the factual preconditions for a reasonable hypothesis.

This instrument does not prescribe penalties. It is not a penal or regulatory instrument. Enforcement is through the standard mechanisms of the veterans’ entitlements system: if a decision-maker incorrectly applies the SoP, the claimant can seek internal review by the Veterans’ Review Board, and further review by the Administrative Appeals Tribunal and the Federal Court. There are no criminal penalties for claimants who make false statements, but such conduct would be dealt with under the Criminal Code or specific provisions of the VEA or MRCA. The SoP itself contains no penalty provisions. The enforcement risk for the Commonwealth is that a decision not to apply the SoP correctly could be set aside, leading to back-payment of benefits plus interest. For claimants, the risk is that failure to prove a factor means the claim is rejected. The SoP does not create any compliance costs in the traditional sense; it is a determination that guides adjudication. However, the cost of proving a factor can be substantial, especially for cumulative radiation dose, which may require expert reconstruction from service records, medical imaging records, or nuclear test participation files. Those costs are borne by the claimant or the Commonwealth depending on the funding mechanism. The instrument does not impose any monitoring or reporting obligations. The RMA is not required to periodically review this SoP, but it can amend or revoke it if the medical evidence changes. There is no sunset clause. The SoP does not create any private rights of action; it only operates within the compensation system. The enforcement hierarchy is clear: the SoP sits below the VEA and MRCA. If the SoP were inconsistent with the parent legislation, the legislation would prevail. The RMA’s power to make SoPs is limited by the requirement for sound medical-scientific evidence, and a court could invalidate an SoP if it were not based on such evidence. This has happened occasionally. In practice, the biggest enforcement risk is that decision-makers misunderstand the definitions or timeframes, leading to erroneous acceptance or rejection of claims. The SoP’s detailed definitions are designed to reduce that risk but also create technical hurdles.

The SoP is made under subsection 196B(2) of the VEA and must be read together with Part XIA of that Act, which governs Statements of Principles. It also interacts with section 120A of the VEA, which sets out the reasonable hypothesis standard for claims involving operational service. For MRCA claims, it interacts with section 338 of that Act. The SoP revokes the earlier No. 19 of 2009, so any claim assessed before 29 January 2018 that was later reconsidered may still be subject to the old instrument if the claim was finally determined. The instrument does not apply to claims under the Safety, Rehabilitation and Compensation (Defence-related Claims) Act 1988, but similar principles may apply under separate instruments. Section 11 incorporates other SoPs: if a factor refers to an injury or disease covered by another SoP (e.g., a drug treatment that causes another condition), the decision-maker must apply that SoP in accordance with its terms as in force from time to time. This creates a cross-referencing system. The dictionary defines “cumulative equivalent dose” by reference to the ARPANSA guide, which is a non-legislative document, meaning the guide’s methodology is adopted as binding. Changes to that guide would affect the SoP without amendment. Similarly, the ICD-10-AM coding is referenced but only for identification; the substantive meaning is in subsection 7(2). The SoP interacts with the general law of evidence: for example, the burden of proof is on the claimant to show the factor existed, but the standard for the hypothesis is lower. It also interacts with privacy laws when medical records are obtained. The SoP does not override state or territory workers’ compensation laws; it is specific to Commonwealth military compensation. It does not affect tort claims against third parties. The instrument may also interact with international agreements, such as those concerning nuclear test veterans. The definition of “relevant service” includes British nuclear test defence service, which is a specific category under the VEA. The SoP is silent on how it interacts with other medical causation standards such as those in the Social Security Act 1991. It is a standalone instrument but operates as part of a larger body of SoPs covering many conditions. The RMA is required to keep SoPs consistent across conditions; for example, the obesity factor appears in many SoPs. This instrument’s definitions for “being overweight or obese” are uniform across SoPs. The SoP does not purport to amend any other legislation. It has the force of law as a legislative instrument and must be registered under the Legislation Act 2003.

The SoP is a new instrument that commenced on 29 January 2018. It revokes the previous SoP concerning cerebral meningioma, No. 19 of 2009, as amended. The 2009 instrument was made under both subsections 196B(2) and (8) of the VEA, indicating it covered both reasonable hypothesis and reasonable satisfaction standards. This 2018 instrument is made only under subsection 196B(2), meaning it applies only to the reasonable hypothesis standard. The SoP does not provide an amendment history of the 2009 instrument. It does not include any transitional provisions. The instrument itself has not been amended as of its date. The RMA may issue amending instruments in the future if medical evidence changes. The revocation of the 2009 SoP means that any claim made after commencement must be assessed under the new factors, even if the condition was discovered earlier. The SoP does not specify whether it applies to claims that were lodged but not determined before commencement; that is governed by the VEA and MRCA provisions. The instrument does not contain a savings provision for the old SoP. There is no explanatory memorandum attached, but the RMA typically publishes a statement of reasons. The SoP’s commencement date of 29 January 2018 is 38 days after it was made on 22 December 2017. This is standard. The instrument is No. 1 of 2018, indicating it is the first SoP made that year. The previous SoP would have had a similar number. The SoP does not amend any other legislative instruments. It is a complete replacement. The revocation of the 2009 SoP may affect claims that were in progress: if a claimant had relied on a factor in the 2009 SoP that is no longer included, they cannot succeed unless they meet one of the new factors. Conversely, new factors (such as the specific drug list) may benefit some claimants who did not succeed before. The instrument does not indicate any transitional period for existing claims.

The source text does not cite any litigation history. Statements of Principles under Part XIA of the VEA have been the subject of judicial review in the Federal Court and High Court in other contexts, but no cases are mentioned in this instrument. The Repatriation Medical Authority’s determinations have been challenged on grounds such as failure to consider sound medical-scientific evidence, unreasonable exercise of power, and procedural fairness. For example, in Repatriation Commission v. Hill (2002) 119 FCR 231, the Federal Court considered the standard for SoPs. However, the source does not reference any case specific to cerebral meningioma. The absence of litigation history in the instrument does not mean there have been no court cases applying this SoP. The SoP is applied in thousands of administrative decisions each year, many of which are reviewed by the Veterans’ Review Board. Board decisions are not binding precedent but can influence the interpretation of factors. The instrument itself is not subject to litigation in the traditional sense; rather, it is the application of the SoP that is litigated. There is no record in the source of any challenge to the 2018 SoP itself. The earlier 2009 SoP may have been subject to challenge, but that is not relevant. The SoP’s detailed definitions are designed to reduce litigation risk by increasing certainty. However, the narrowness of definitions may generate disputes about what constitutes a continuous period of treatment, or whether a particular estrogen-progesterone combination falls within “hormone replacement therapy”. The interaction with other SoPs under section 11 could also lead to litigation if there is disagreement about which SoP applies. The instrument does not contain any severability clause, but if a factor were struck down by a court, the rest of the SoP would likely remain valid. The SoP is not a compendium of legal precedent; it is administrative legislation.

Several traps await the unwary claimant or adviser. First, the cumulative equivalent dose factor (9(1)) requires a minimum of 0.1 sievert to the brain, calculated per the ARPANSA guide, but excludes normal background radiation in Australia. This means a claimant who received diagnostic x-rays must calculate the dose to the brain, not just the entrance dose, and must exclude background. The five-year latency period is strict; radiation exposure less than five years before onset does not count. Second, the obesity factor (9(2)) uses a BMI threshold of 25, which is merely overweight, not obese. A BMI of 25 for at least five years within the 20 years before onset raises the hypothesis. This is a broad net, but the claimant must show that the obesity was related to service. If a veteran became overweight due to a service injury causing reduced mobility, that may be easier. But if the obesity is unrelated, the factor does not help. Third, the pregnancy factor (9(3) and 9(6)) only applies during the second or third trimester or within 30 days postpartum. It does not cover first trimester or later periods. It also only applies to clinical onset or worsening; it does not cover the entire latency period. Fourth, the drug factor (9(4) and 9(7)) is extremely narrow: only four specific progestins at specific daily doses for a continuous period of at least one year. Many common drugs, such as oral contraceptives containing different progestins, are excluded. Cyproterone acetate is used in prostate cancer and some hormonal conditions, but the dose must be at least 15 mg/day. Medroxyprogesterone acetate includes Depo-Provera injections, but the daily dose equivalent must be at least 15 mg. The SoP does not specify how to calculate dose for injectable forms; the ARPANSA guide is for radiation, not drugs. This ambiguity could trap claimants. Fifth, the hormone replacement therapy factor (9(5)) requires at least six months of continuous use and a 10-year post-cessation window. This excludes short-term HRT. It also defines HRT narrowly as for menopause deficiency, not for other indications. Sixth, the clinical worsening factors (9(6)-9(8)) apply only to material contribution or aggravation, and only if the condition was suffered or contracted before or during service but did not arise out of it. This means that if a veteran already had cerebral meningioma before service, and service worsened it, the worsening must be related to one of those factors. The inability to obtain appropriate clinical management factor (9(8)) is vague: it does not define what constitutes appropriate management or why the inability must be related to service. This could lead to disputes about whether lack of access to a neurosurgeon in a remote posting qualifies. Seventh, the “relationship to service” requirement in section 10 is separate from the factor existence. Even if the factor exists, the claimant must show the factor itself was related to service. For example, a veteran who used hormone replacement therapy for menopause after discharge must show the HRT was taken for a menopausal condition linked to service, perhaps due to a bilateral oophorectomy from a service injury. This two-step causation chain is easily overlooked. Eighth, the dictionary definition of “being treated with a drug as specified” uses “taking daily” for oral drugs but “receiving” for medroxyprogesterone acetate (which can be injectable). This inconsistency may cause confusion about continuous periods when injections are spaced. Ninth, the SoP does not cover malignant meningiomas. A tumour that is intermediate grade (atypical) is covered, but not anaplastic (malignant). The ICD-10-AM code D32.9 covers benign, D32.0 covers benign cerebral meninges. Malignant code C70.0 is excluded. Claimants with malignant tumours must look to other SoPs or rely on the reasonable hypothesis standard without a specific SoP. Tenth, the SoP only applies to reasonable hypothesis claims. For claims that require proof on the balance of probabilities (such as non-operational service under VEA or MRCA non-warlike service under certain circumstances), a different SoP (made under subsection 196B(8)) may exist, but this instrument is only for the lower standard. Claimants with non-operational service may not benefit from this SoP unless the MRCA warlike/non-warlike definition applies.

For a claimant seeking compensation for cerebral meningioma, the first step is to identify which factor(s) in section 9 may apply. The most straightforward factors are obesity and pregnancy/postpartum status, but these require proof of BMI over 25 for at least five years within the 20 years before onset, or pregnancy timing. Claimants should gather medical records showing weight and height at relevant times, or obstetric records. For the radiation factor, the claimant must obtain an estimate of cumulative equivalent dose to the brain from all sources (medical imaging, nuclear test participation, aircrew exposure) calculated per the ARPANSA guide. This may require a specialist radiation dosimetrist. For the drug factor, the claimant must identify whether they took any of the four specified drugs at the specified dose for a continuous period of at least one year. Pharmacy records, prescription histories, and medical notes are needed. For the HRT factor, records of estrogen-progesterone therapy for menopausal symptoms for at least six continuous months are required, with onset within 10 years of cessation. The claimant must also establish that the factor is related to their relevant service. For example, if the factor is obesity, the claimant must show the obesity resulted from a service injury, service lifestyle factors, or medical condition arising from service. This requires additional evidence linking the factor to service. Claimants should obtain service medical records, personnel records, and any documentation of nuclear test participation or aircrew duties. If the condition has worsened after onset, the claimant should examine whether any of subsections 9(6) to 9(8) apply, but only if the condition was suffered or contracted before or during service but not arising out of it. This is complex and likely requires legal advice. Claimants should also be aware of the 10-year and 5-year latency periods; the factors require the exposure or condition to have occurred before clinical onset by specific minimum periods. The instrument requires the factor to exist before the clinical onset or worsening. For death claims, the claimant must show that the cerebral meningioma contributed to a terminal event. The definition of terminal event includes five specific causes, but other causes may be covered if they are the proximate or ultimate cause of death. The claimant should obtain a death certificate and any autopsy or medical report linking the tumour to death. For legal practitioners, compliance means carefully matching the client’s history to the factors and preparing evidence that satisfies the definitions. Inability to obtain appropriate clinical management (factor 9(8)) is notably vague; practitioners should argue if a veteran could not access neurosurgery due to remote posting or service-related delays. However, this factor has not been tested. For decision-makers, compliance means applying the SoP strictly and not extending factors by analogy. For example, a drug similar to the listed progestins but not specifically named does not qualify. The decision-maker must also check the ARPANSA guide for dose calculations and the ICD-10-AM edition referenced. The SoP is in force from 29 January 2018; any claim lodged before that date but assessed after must use this SoP if the claim is still pending. The RMA itself must ensure its determination is based on sound medical-scientific evidence, though this is not a compliance task for claimants. The instrument does not require periodic reporting or ongoing compliance; it is applied at the time of claim assessment. Overall, compliance hinges on meticulous record-keeping and strict adherence to the letter of the definitions.